McKesson pivots to North America

Article Excerpt

MCKESSON CORP. $333 is a buy for aggressive investors. The company (New York symbol MCK; Aggressive Growth Portfolio, Consumer sector; Shares outstanding: 149.8 million; Market cap: $49.9 billion; Price-to-sales ratio: 0.2; Dividend yield 0.6%; TSINetwork Rating: Above Average; www.mckesson.com) recently sold its European operations so it can focus on its more-profitable North American drug distribution and drugstore businesses. In all, it received roughly $1.8 billion. Revenue in its fiscal 2022 fourth quarter, ended March 31, 2022, rose 11.8% to $66.10 billion from $59.14 billion a year earlier. That’s partly due to its role in distributing COVID-19 vaccines in the U.S. Earnings per share also improved 15.4%, to $5.83 from $5.05. The stock has jumped over 70% in the past year. Even so, it still trades at just 14.2 times the $23.37 a share that McKesson will probably earn in fiscal 2023. The $1.88 dividend yields 0.6%. McKesson is a buy. buy…